Navigation Links
Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer

EDMONTON, Jan. 28 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. ("Quest" or the "Company") today announced that it has signed a collaborative research agreement with the BC Cancer Agency (the "BCCA") to develop a combination therapy for the treatment of lung cancer. The potential treatment will utilize the Company's lead oncology product, SL052, with various immunotherapeutic agents. Research has shown that photodynamic therapy (PDT) can augment the therapeutic effects of immunomodulators such as antibodies, antigens, cytokines and immunoadjuvants in cancer patients.

Under the terms of the agreement, the BCCA, with Dr. Mladen Korbelik as the principle investigator, will investigate therapeutic and mechanistic aspects of anti-tumor effects achieved by combining photodynamic therapy (PDT) based on Quest's photosensitizer, SL052, with various immunotherapeutic agents.

PDT uses light to activate anti-cancer drugs, but has also been shown to stimulate the body's immune system to fight the disease. Dr. Korbelik, a Senior Scientist at the BCCA and a Clinical Professor at the University of British Columbia, is a pioneer and leader in this area of research. For the past 20 years, he has been involved in PDT studies aimed at improving treatment of solid tumors. His research has provided direct evidence of the induction of tumor immunity by PDT; and demonstrated that PDT can be effectively potentiated by adjuvant immunotherapy.

"Using targeted treatments with better delivery and manipulating the body's own immune system to fight the disease means patients would experience fewer side effects," said Dr. Korbelik. Quest has a strong intellectual property position to use SL052 with immunotherapy. The combination therapy technology has already received patents from United Kingdom, France, Germany, Switzerland and Australia, and patents are pending in the USA and Canada.


About the BC Cancer Agency: The BCCA, an agency of the Provincial Health Services Authority, is renowned world wide for leading edge research and its population-based approach to cancer care. The mission of the BCCA is to reduce the incidence of cancer; to reduce the mortality rate of people with cancer; and to improve the quality of life of people living with cancer. With more than 2000 employees, the BCCA provides a comprehensive cancer control program for the people of British Columbia which links prevention, early detection, diagnosis and treatment, supportive care, rehabilitation, palliative care, education, research, and support for community programs. In recognition that its provincial mandate to effect cancer control for the province cannot be realized via current methods of cancer treatment that are aimed at treatment of late stage disease, the BCCA has placed emphasis upon translational research to spearhead new modalities in cancer control, particularly those aimed at early detection and more effective therapeutic interventions.

About Quest PharmaTech Inc: Quest PharmaTech Inc. is a publicly traded (TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to build shareholder value through discovery, development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platform. The Company's lead dermatology product, SL017, is a topical formulation that is currently undergoing a 90 patient clinical trial in Canada for hair removal applications. The Company's lead oncology product, SL052, is scheduled to enter a Phase I clinical trial during the second half of 2008. Quest recently signed an agreement with a multinational technology development company to receive $3,000,000 to develop oncology products based on its SonoLight technology.

"TSX Venture Exchange has neither approved nor disapproved of the

information contained herein."

Web site:

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
Breaking Biology News(10 mins):